CD44 and neoplasm: Bulk tumour cells and both AR and CD24low/CD44+ BCSCs effectively sensed cisplatin-ICLs, mounting a comparably robust FA/DSB response following pulse cisplatin treatment (2 h), as evidenced by FANCD2 and initial 53BP1 recruitment respectively (Fig. 1D–F).